Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1241-1252

  Lui, Vivian Wai Yan ^a,d   Lau, Cecilia Pik Yuk ^b   Ho, KaKiu ^b   Ng, Margaret Heung Ling ^a   Cheng, Suk Hang ^a   Tsao, Sai Wah ^c   Tsang, Chi Man ^c   Lei, Kenny Ieng Kit ^a   Chan, Anthony T C ^a   Mok, Tony Shu Kam ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Hong Kong Cancer Institute   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anoikis sensitization; Anti invasion; Lapatinib; NPC

Indexed keywords

CASPASE 3; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; SURVIVIN; ANTINEOPLASTIC AGENT; HER2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANOIKIS; ANTIINVASION ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; ENZYME MODIFICATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANOIKIS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84855522943     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9470-y     Document Type: Article

References (65)

1. Anderson KE, Mack TM, Silverman DT (2006) Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 721-762
2. Chan AT, Teo PM, Johnson PJ (2002) Nasopharyngeal carcinoma. Ann Oncol 13(7):1007-1015
3. Teo PM, Kwan WH, Lee WY et al (1996) Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77(12):2423-2431 (Pubitemid 26169137)
4. Lui VW, Wong EY, Ho Y et al (2009) STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 125(8):1884-1893
5. Ma BB, Lui VW, Poon FF et al. (2009) Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs.
6. Ma BB, Poon TC, To KF et al (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 25(10):864-872 (Pubitemid 37139899)
7. Leong JL, Loh KS, Putti TC et al (2004) Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114(1):153-157 (Pubitemid 38141085)
8. Chua DT, Nicholls JM, Sham JS et al (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59(1):11-20 (Pubitemid 38501502)
9. Taheri-Kadkhoda Z, Magnusson B, Svensson M et al (2009) Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 31(4):482-492
10. Lui VW, Yau DM, Wong EY et al (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30(12):2085-2094
11. Hu LF, Chen F, Zhen QF et al (1995) Differences in the growth pattern and clinical course of EBV-LMP1 expressing and nonexpressing nasopharyngeal carcinomas. Eur J Cancer 31 A (5): 658-660
12. Gondhowiardjo S (2000) Epstein-Barr virus latent membrane protein 1(EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. Gan To Kagaku Ryoho 27 (Suppl 2):323-331
13. Horikawa T, Sheen TS, Takeshita H et al (2001) Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol 159(1):27-33 (Pubitemid 33704188)
14. Tao Y, Song X, Deng X et al (2005) Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 303(2):240-251 (Pubitemid 40126259)
15. Miller WE, Earp HS, Raab-Traub N (1995) The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69(7):4390-4398
16. Zheng X, Hu L, Chen F et al (1994) Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 30 B (5): 290-295 (Pubitemid 24309207)
17. Yan J, Fang Y, Jiao Y (2001) Significance of her2 oncogene expression in primary nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi 81(15):904-906
18. Jin O, Chen S, Li G et al (1997) Expression of CerbB-2 and EGFR mRNA in human nasopharyngeal carcinomas and pericarcinomatous tissues. Hunan Yi Ke Da Xue Xue Bao 22(6):487-490
19. Bar-Sela G, Kuten A, Ben-Eliezer S et al (2003) Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 16(10):1035-1040 (Pubitemid 37280820)
20. Roychowdhury DF, Tseng A Jr, Fu KK et al (1996) New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 77(8):1419-1426 (Pubitemid 26105375)
21. Yazici H, Altun M, Alatli C et al (2000) c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest 18(1):6-10 (Pubitemid 30080778)
22. Cavalot A, Martone T, Roggero N et al (2007) Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29(7):655-664 (Pubitemid 47168236)
23. Cappuzzo F, Magrini E, Ceresoli GL et al (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 96(15):1133-1141 (Pubitemid 39207049)
24. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500 (Pubitemid 38720929)
25. Kim HP, Han SW, Kim SH et al (2008) Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 7(3):607-615
26. Janne PA (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer 60 (Suppl 2): S3-S9 (Pubitemid 351726031)
27. Zhou W, Ercan D, Chen L et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276):1070-1074
28. Guo A, Villen J, Kornhauser J et al (2008) Signaling networks assembled by oncogenic EGFR and c-Met. ProcNatlAcad SciU S A 105(2):692-697 (Pubitemid 351171770)
29. Ma B, Hui EP, King A et al (2008) A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 62(1):59-64 (Pubitemid 351537846)
30. Chua DT, Wei WI, Wong MP et al (2008) Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 30(7):863-867 (Pubitemid 352008945)
31. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043 (Pubitemid 46799492)
32. Li G, Wang Y, Huang K et al (2005) The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol 32(1):59-65 (Pubitemid 40187382)
33. Glaser R, Zhang HY, Yao KT et al (1989) Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A 86(23):9524-9528 (Pubitemid 20010459)
34. Sizhong Z, Xiukung G, Yi Z (1983) Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 31(5):587-590 (Pubitemid 13058335)
35. Huang DP, Ho JH, Poon YF et al (1980) Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 26(2):127-132 (Pubitemid 10086410)
36. Cheung ST, Huang DP, Hui AB et al (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83(1):121-126 (Pubitemid 29409487)
37. Lo AK, Lo KW, Tsao SW et al (2006) Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8(3):173-180 (Pubitemid 43671232)
38. Lui VW, Boehm AL, Koppikar P et al (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71(5):1435-1443 (Pubitemid 46658696)
39. Lui VW, Thomas SM, Zhang Q et al (2003) Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22(40):6183-6193 (Pubitemid 37281648)
40. Yan J, Fang Y, Huang BJ et al (2002) Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet Cytogenet 132(2):116-119 (Pubitemid 34170868)
41. Rusnak DW, Alligood KJ, Mullin RJ et al (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2(ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40 (4):580-594 (Pubitemid 47063294)
42. Konecny GE, Venkatesan N, Yang G et al (2008) Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98(6):1076-1084 (Pubitemid 351399811)
43. Rusnak DW, Lackey K, Affleck K et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1(2):85-94
44. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3):1630-1639 (Pubitemid 43259947)
45. Kim JW, Kim HP, Im SA et al (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272(2):296-306
46. D'Alessio A, De Luca A, Maiello MR et al. (2009) Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat.
47. Xia W, Gerard CM, Liu L et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24(41):6213-6221 (Pubitemid 43080044)
48. Kedrin D, Wyckoff J, Boimel PJ et al (2009) ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res 15(11):3733-3739
49. Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13(5):555-562 (Pubitemid 32817013)
50. Chan AT (2005) Head and neck cancer: treatment of nasopharyngeal cancer. Ann Oncol 16 (Suppl 2): ii265-ii268 (Pubitemid 40908969)
51. Kaufman B, Trudeau M, Awada A et al (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10(6):581-588
52. Toi M, Iwata H, Fujiwara Y et al (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101(10):1676-1682
53. Johnston S, Trudeau M, Kaufman B et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2(HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26 (7):1066-1072
54. Sridhar SS, Hotte SJ, Chin JL et al. (2009) A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer. Am J Clin Oncol.
55. Burris HA 3rd, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23):5305-5313 (Pubitemid 46206984)
56. Spector NL, Xia W, Burris H 3rd et al (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23(11):2502-2512 (Pubitemid 47050840)
57. Zhang D, Pal A, Bornmann WG et al (2008) Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7(7):1846-1850
58. Xia W, Bisi J, Strum J et al (2006) Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 66(3):1640-1647 (Pubitemid 43259948)
59. Xiang Y, Yao H, Wang S et al (2006) Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope 116(1):126-130 (Pubitemid 44383976)
60. Hegde PS, Rusnak D, Bertiaux M et al (2007) Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 6(5):1629-1640 (Pubitemid 46954030)
61. Ryan Q, Ibrahim A, Cohen MH et al (2008) FDA drug approval Summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13(10):1114-1119
62. Higa GM, Abraham J (2007) Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 7(9):1183-1192 (Pubitemid 47521015)
63. Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18):2999-3005
64. Azim H, Azim HA Jr, Escudier B (2009) Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 35(7):633-638
65. Cathomas R, von Moos R (2009) Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib. Ann Oncol 20(9):1606-1607